CN104490965B - The application of panax japonicus polysaccharides, panax japonicus total saponins and panax japonicus saponin V - Google Patents
The application of panax japonicus polysaccharides, panax japonicus total saponins and panax japonicus saponin V Download PDFInfo
- Publication number
- CN104490965B CN104490965B CN201410721839.4A CN201410721839A CN104490965B CN 104490965 B CN104490965 B CN 104490965B CN 201410721839 A CN201410721839 A CN 201410721839A CN 104490965 B CN104490965 B CN 104490965B
- Authority
- CN
- China
- Prior art keywords
- panax japonicus
- total saponins
- polysaccharides
- panax
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
Abstract
The invention discloses application of the composition of panax japonicus polysaccharides, panax japonicus total saponins, panax japonicus saponin V and panax japonicus polysaccharides and panax japonicus total saponins in the medicine for preparing prevention and treatment COPD.Drug side-effect of the invention containing mentioned component is small, comes from single plant, and composition is simple, clear and definite for preventing and treating COPD curative effects.
Description
Technical field
The invention belongs to drug field, and in particular to panax japonicus polysaccharides, panax japonicus total saponins and panax japonicus saponin V are in medicine
Application in preparation.
Background technology
COPD (chronic obstructive pulmonary disease, COPD) is a kind of
The disease that can be prevented and treated with flow limitation feature, flow limitation is not fully reversible, in sexual development is carried out, with lung
Abnormal inflammatory reaction to the pernicious gases such as smoke from cigarette or deleterious particle is relevant, and its chronic inflammatory reaction is real throughout air flue, lung
Matter and Pulmonary Vascular.COPD mainly involves lungs, but can also cause the ill effect of whole body (or outside lung).
COPD is chronic disease common in a kind of global range, is number four at present in the global cause of death, according to the world
Health organization predicts that, to the year two thousand twenty, COPD will be number five in global disease morbidity, and will be number three in the cause of death.In recent years
Come, China COPD incidence of disease is in rising trend, the illness rate of more than 40 years old crowd is 9% ~ 10%, and illness rate is high within more than 60 years old
Up to 13% ~ 30%, the annual number dead because of COPD in the whole nation is up to 1,000,000.
Clinical manifestation common COPD has chronic cough, expectoration, shortness of breath or expiratory dyspnea, panted and the symptom such as uncomfortable in chest,
In the clinical process of disease, especially in heavier patient, it may occur that systemic symptoms, such as Body weight loss, anorexia, periphery
Muscular atrophy and dysfunction, mental depression and (or) anxiety etc..
COPD pathogenesis is not yet fully apparent from.Generally believe that the cell for participating in COPD has neutrophil leucocyte, T to drench at present
The inflammatory cell such as bar cell and macrophage, discharges a variety of inflammatory mediators after cell is activated, such as leukotriene B4 (LTB4),
Interleukin 8 (IL-8), tumor necrosis factor α (TNF-α), GELB (MMP-9) etc., participate in pulmonary parenchyma and break
The inflammatory reactions such as bad, Pulmonary Vascular.Its pathological change feature shows as alveolar space inflammatory cell (such as macrophage) infiltration, ramuscule gas
Pipe and peribronchiolar stove inflammatory cell infiltration, the expansion of lung tissue edge alveolar space, destruction, alveolar wall broaden, its epithelium
Cellular swelling, be rounded, partial exfoliation.
At present, COPD treatment mainly includes bronchodilators, glucocorticoid, antibiotic, oxygen therapy and mechanical ventilation
Deng.Data shows that medicine can mitigate symptom, increase locomitivity, reduce acute episode frequency and the order of severity, and improve health
State and exercise tolerance, but these side effects of pharmaceutical drugs are very big, it is therefore, eager to need to develop to come from single plant, into
Divide simple, the clear and definite active component of curative effect, active ingredient or active principle, for preventing and treating COPD.
The content of the invention
In order to solve the above-mentioned technical problem, the invention provides panax japonicus polysaccharides, panax japonicus total saponins or panax japonicus polysaccharides
With the application of the compositions of panax japonicus total saponins in the medicine for preparing prevention and treatment COPD.
Preferably, the mass ratio of panax japonicus polysaccharides and panax japonicus total saponins is 1 in above-mentioned composition:3~3:1.It is further excellent
The mass ratio of selection of land, panax japonicus polysaccharides and panax japonicus total saponins is 1:1
Present invention also offers panax japonicus saponin V answering in the medicine for preparing prevention and treatment COPD
With.
Present invention also offers a kind of medicine for preventing and treating COPD, contain panax japonicus polysaccharides or bamboo
One of section ginseng total saposins or composition.
Preferably, the mass ratio of panax japonicus polysaccharides and panax japonicus total saponins is 1 in above-mentioned composition:3~3:1.More preferably
The mass ratio of panax japonicus polysaccharides and panax japonicus total saponins is 1 in ground, above-mentioned composition:1.
Further, pharmaceutically acceptable carrier can also be contained in above-mentioned medicine.
Present invention also offers a kind of medicine for preventing and treating COPD, contain panax japonicus saponin V.
Further, pharmaceutically acceptable carrier can be also contained in said medicine.
Pharmaceutically acceptable carrier includes the auxiliary material of oral formulations auxiliary material or Parenteral.Method of administration can be with
It is oral, injection, local administration etc..Technique according to the invention scheme, said composition can be oral formulations or injection system
Agent, wherein oral formulations include capsule, soft capsule, granule, oral liquid, tablet, dripping pill etc..Auxiliary material used includes:Form sediment
It is powder, sucrose, lactose, Icing Sugar, glucose, mannitol, xylitol, polyethylene glycol, isopropanol, temperture of leaves -80, glycerine, propane diols, micro-
It is crystalline cellulose sodium, dextrin, cyclodextrin, sodium chloride, vitamin C, half skin propylhomoserin, citric acid, sodium thiosulfate, sodium sulfite, hard
The customary adjuvant such as resin acid salt and gelatin, the later stage preparation technology and equipment of preparation belong to the routine techniques of pharmaceutical field, the present invention
This is not construed as limiting, therefore is not described in detail herein.
The combination of panax japonicus polysaccharides, panax japonicus total saponins, panax japonicus polysaccharides and panax japonicus total saponins in the application of the present invention
PFT that thing or panax japonicus saponin V tools are significantly improved the mouse COPD models that lipopolysaccharides and cigarette induce jointly is low,
Flow limitation and cough, breathe heavily, uncomfortable in chest etc., and Small side effects, come from single plant, composition is simple, bright for preventing and treating COPD curative effects
Really.
Panax japonicus polysaccharides of the present invention, panax japonicus total saponins and panax japonicus saponin V are extracted from Chinese medicine panax japonicus and obtained.
Panax japonicus is conventional Chinese herbal medicine, there is long-term traditional Chinese medical science medication experience, and the medicine is safe to use, no overt toxicity effect note
Carry.
Panax japonicus polysaccharides, panax japonicus total saponins, its composition and panax japonicus saponin V have definite improvement animal pattern lung
Hypofunction, flow limitation and cough, the effect breathed heavily etc..Therefore, panax japonicus polysaccharides, panax japonicus total saponins and panax japonicus saponin V
With the prospect for developing into prevention and treatment COPD medicines.
Embodiment
With reference to specific embodiment, the invention will be further described, so that those skilled in the art can be more preferable
Understand the present invention and can be practiced, but illustrated embodiment is not as a limitation of the invention.
Panax japonicus is Araliaceae Panax herbaceos perennial Panax japonicus C. A. Mey. dry root.
Original is a kind of rare Chinese herbal medicine among the people, first recorded in《A Supplement to the Compendium of Materia Medica》, recorded in《Pharmacopoeia of People's Republic of China》,
The similar ginseng of medicinal function and pseudo-ginseng.Panax japonicus is born in by hillside limes marginis, dark and damp area or rock ditch ravine.It is distributed mainly on expensive
The ground such as state, Hunan, Yunnan, Anhui, Jiangxi, Hubei.Annual autumn excavation, removes cauline leaf, separates fleshy root, rhizome is removed outer
Skin, drying or drying in the shade to be used as medicine.Panax japonicus is sweet, slight bitter, warm-natured, many with promoting blood circulation and removing blood stasis, swelling and pain relieving, strengthening by means of tonics etc.
Plant effect.The strengthening by means of tonics effect of existing similar ginseng, there is blood stasis removing analgesic, hemostasis, the phlegm-dispelling functions of similar pseudo-ginseng again, main to use
In eak after being ill, overstrain cough hemoptysis, coughing with a lot of sputum, traumatic injury etc..Contain a variety of saponin(es, volatile oil, carbohydrate and many in panax japonicus
Plant amino acids chemical composition.
Extraction, purifying and the preparation of the panax japonicus polysaccharides of embodiment one
Panax japonicus coarse powder is taken, the water of 10 times of amounts is added, after soaking 2 hours, decocts and extracts 2 hours, filtration obtains filtrate.Medicine
Slag is again with the water boiling and extraction 2 times of 8 times of amounts, 1.5 hours every time, filtration.Merge 3 filtrates, be concentrated under reduced pressure into appropriate volume.Plus
High concentration ethanol is placed more than 12 hours under being 65%, normal temperature to concentration of alcohol into concentrate, and filtration collects sediment, repeatedly
Alcohol precipitation 2 times, merges sediment, freeze-dried, obtains panax japonicus polysaccharides.
Extraction, purifying and the preparation of the panax japonicus total saponins of embodiment two
Panax japonicus coarse powder is taken, 60% ethanol of 10 times of amounts is added, soaked 2 hours, water-bath refluxing extraction 2 hours, filtration,
Obtain filtrate.The dregs of a decoction are extracted 2 times with 60% alcohol reflux of 8 times of amounts again, 1.5 hours every time, filtration.Merge 3 filtrates, decompression
Ethanol is reclaimed to without alcohol taste, medicinal material is configured to：Decoction (g/m1) is 1:2.5 solution.On the HP-400 macropores handled well
Resin column, successively with water, 60% ethanol elution.The ethanol eluate of merging 60%, recycling design is freeze-dried near dry,
Obtain panax japonicus total saponins.
The panax japonicus saponin V of embodiment three extraction, purifying and preparation
Panax japonicus coarse powder is taken, 60% ethanol of 10 times of amounts is added, after soaking 2 hours, refluxing extraction 2 hours, filtering is obtained
Filtrate, the dregs of a decoction are extracted 2 times with 60% alcohol reflux of 8 times of amounts again, 1.5 hours every time, filtering.Merge three filtrates, depressurize back
Ethanol is received to without alcohol taste, medicinal material is configured to：Decoction（g/ml）For 1:2.5 solution.On the HPD-400 macropore trees handled well
Fat post, successively with water, 60% ethanol elution.The ethanol eluate of merging 60%, recycling design is closely dry, is dried under reduced pressure through 65 DEG C,
Obtain panax japonicus total saponins.Panax japonicus total saponins are purified through HP-20 resin columns again, collect 55% ~ 85% ethanol eluate, decompression
Ethanol is reclaimed, freeze-drying obtains panax japonicus saponin V, and its purity is more than 90%.
Example IV
The experimental study of panax japonicus polysaccharides, panax japonicus total saponins and panax japonicus saponin V prevention and treatments COPD
1. experiment material
1. 1 medicine and reagent
Bricalin piece (HaiNan Kangzhi Pharmaceutical Co., Ltd, lot number 131116)；Lipopolysaccharides（LPS, the U.S.
Sigma companies）；MDA (MDA) and superoxide dismutase (SOD) kit（Bioengineering Research Institute is built up in Nanjing）；It is swollen
Tumor necrosis factor α (TNF-α) and IL-10 (IL-10) kit（Wuhan Boster Biological Technology Co., Ltd.）；Panax japonicus
Polysaccharide (DT), panax japonicus total saponins (ZG), panax japonicus saponin V（ZV）Made by oneself for this laboratory.
1. 2 laboratory apparatus
TE-CAr all-wave length multi-function microplate readers (model SAFIRE2)；LXJ-II centrifuges (Shanghai medical analytical instrument
Factory)；Satrious electronic balances (Germany)；Thermostat water bath (Shanghai Yarong Biochemical Instrument Plant)；(it is beautiful for low-temperature and high-speed centrifuge
Z323K)；RSFJ800 pulmonary function test apparatus (Chengdu Sheng Science and Technology Ltd.s)；Liquid-transfering gun（Big dragon）.
1.3 experimental animal
Healthy cleaning grade Wistar rats 56, male, body weight 200g ± 20g, by the Central China University of Science and Technology, animal center is carried
For.
2. the preparation of laboratory sample
Panax japonicus polysaccharides, panax japonicus total saponins and the panax japonicus saponin V prepared in embodiment one, two, three.
3. the preparation of test specimen liquid
3.1. the preparation of CMC-Na solution：Precision weighs 4 g CMC-Na and is dissolved in 1000 mL distilled water, is configured to dense
Spend the CMC-Na solution for 0. 4%.
3.2. prepared by positive control solution：Weigh bricalin piece appropriate, be placed in mortar and be ground into fine powder, be dissolved in
In appropriate CMC-Na solution, 0.1mg/ml bricalin suspension is obtained, is positive control decoction.
3.3. the preparation of DT decoctions：It is appropriate that precision weighs DT.It is dissolved in appropriate CMC-Na solution, obtains 2.0 mg/ml's
DT suspensions.
3.4. the preparation of ZG decoctions：It is appropriate that precision weighs ZG.It is dissolved in appropriate CMC-Na solution, obtains 2.0 mg/ml's
ZG suspensions.
3.5.ZV the preparation of decoction：It is appropriate that precision weighs ZV.It is dissolved in appropriate CMC-Na solution, obtains 1.0 mg/ml's
ZV suspensions.
3.6. DT+ZG（1）The preparation of decoction：It is appropriate that precision weighs ZG and DT.It is dissolved in appropriate CMC-Na solution, obtains
It is respectively 1.0 and 1.0 mg/ml suspension containing DT and ZG.（That is DT：ZG = 1:1）
3.7. DT+ZG（2）The preparation of decoction：It is appropriate that precision weighs ZG and DT.It is dissolved in appropriate CMC-Na solution, obtains
It is respectively 1.5 and 0.5 mg/ml suspension containing DT and ZG.（That is DT：ZG = 3:1）
3.8. DT+ZG（3）The preparation of decoction：It is appropriate that precision weighs ZG and DT.It is dissolved in appropriate CMC-Na solution, obtains
It is respectively 0.5 and 1.5 mg/ml suspension containing DT and ZG.（That is DT：ZG = 1:3）
4. experimental method
4.1 animal packet：Healthy cleaning grade Wistar rats 72, male, body weight 200g ± 20g are divided at random by body weight
For normal group, model group, positive group, DT groups, ZG groups, ZV groups, DT+ZG（1）Group, DT+ZG（2）Group and DT+ZG（3）Group, each group
The free diet of animal, adaptability is used to test after raising one week.
4.2 animal model：Using tracheal strips injection lipopolysaccharides (LPS) superposition fumigation joint modeling.Model group, treatment group
At the 1st day, with 0.7% yellow Jackets (0. 5ml/100g) intraperitoneal injection of anesthesia, dorsal position was fixed on rat fixed plate, cruelly
Reveal glottis, by No. 18 venous catheter needle quick insertion tracheaes, extract nook closing member, physiological saline is dissolved in the injection of 1 ml syringes
The μ L of LPS 200 (1 mg/1ml), then by rat fixed plate vertical rotary, enable LPS to be uniformly distributed in two lungs；Normal group
Implement sham-operation saline injection.Rat was inserted in 60cm × 50cm × 40cm lucite casees in 2nd ~ 56 day, injected
Filter tipped cigarette, the % (vPv) of smoke from cigarette concentration about 5, every morning, afternoon each 1h.
4.3 animals are administered：Using gastric infusion mode, normal group gives 10 ml/kg CMC-Na solution with model group,
Each administration group gives 10 ml/kg decoction respectively, that is, the dosage of positive group is that 1 mg/kg, DT is 20 mg/
Kg, ZG are that 20 mg/kg, ZV groups are 10 mg/kg, DT+ZG（1）Group, DT+ZG（2）Group and DT+ZG（3）It is 20 mg/kg, even
Continuous administration 56 days.
4.4 detection：After last 1 administration 2 hours, in rat eyeground vein clump about 1.2 m1 of blood sampling, serum is separated
(4000rp/min, 10min, 4 DEG C), ELISA kit determines the indexs such as MDA, SOD, TNF-α, IL-10.After blood sampling, Suo Youdong
Thing, according to 0. 5ml/100g intraperitoneal injection of anesthesia, after anesthesia, separates tracheae, in the 3rd the 4th gas with 0. 7% yellow Jackets
Inverted " t " type otch is cut in the middle of pipe ring, then inserts trachea cannula in tracheae, it is then tight with linear system.Animal is put into lung work(
The body of energy analyzer retouches case, and trachea cannula and body are retouched into case gas circuit is connected.Determine 0. 1 seconds forced expiratory volumes of rat
(FEV0.1), FEV0.1With FVC ratio percentage (FEV0.1/ FVC %), 0. 3 seconds forced expiratory volume (FEV0.3), FEV0.3
With FVC ratio percentage (FEV0.3/FVC % )。
5. statistical method
Each group experimental data with mean ± standard deviation (x ± S } represent, and carry out statistical procedures with SPSS 13.0, significantly
Property examine use variance analysis.
6. result is with discussing
The each group rat FEV of table 1.0.1, FEV0.1/ FVC compares (x ± s)
| Group | Number of cases | FEV0.1(L) | FEV0.1 (L)/FVC(%) |
| Normal group | 5 | 1.58±0.12 | 24.25±1.36 |
| Model group | 5 | 1.24±0.24## | 18.52±2.31## |
| Positive group | 6 | 1.56±0.18** | 23.49±2.27** |
| DT groups | 5 | 1.45±0.22** | 22.38±3.32** |
| ZG groups | 6 | 1.42±0.30* | 22.08±2.87* |
| ZV groups | 5 | 1.47±0.16** | 23.20±4.57** |
| DT+ZG groups（1） | 6 | 1.55±0.24*** | 24.03±3.28*** |
| DT+ZG groups（2） | 6 | 1.50±0.22** | 21.32±3.64** |
| DT+ZG groups（3） | 6 | 1.52±0.20** | 23.53±2.78** |
Note:Compared with normal group, #P< 0. 05;Compared with model group, * P<0.05.
Table 2:Each group rat FEV0.3、FEV0.3/ FVC compares (x ± s)
| Group | Number of cases | FEV0.3(L) | FEV0.3 (L)/FVC(%) |
| Normal group | 5 | 6.12±0.36 | 91.36±10.81 |
| Model group | 5 | 4.87±0.28## | 78.83±8.48## |
| Positive group | 6 | 5.62±0.43** | 86.02±7.04** |
| DT groups | 5 | 5.45±0.21** | 85.44±9.31** |
| ZG groups | 6 | 5.22±0.58* | 82.87±9.95* |
| ZV groups | 5 | 5.38±0.49** | 84.99±7.24** |
| DT+ZG groups（1） | 6 | 5.98±0.52*** | 89.73±7.62*** |
| DT+ZG groups（2） | 6 | 5.24±0.52** | 83.73±6.62** |
| DT+ZG groups（3） | 6 | 5.14±0.52** | 85.73±7.21** |
Note:Compared with normal group, #P< 0. 05;Compared with model group, * P<0.05.
From Tables 1 and 2, there is obvious flow limitation in model group compared with normal group, after administration is intervened, flow limitation
Degree is minimized, and is shown that each medicine group has significant improvement result to COPD rat model PFTs, is truly had curative effect.
Table 3:Content of MDA, SOD vitality tests (x ± s)
| Group | Number of cases | MDA(U/ml) | SOD(U/ml) |
| Normal group | 8 | 4.41±1.56 | 72.57±8.29 |
| Model group | 8 | 9.33±3.96## | 62.49±9.89## |
| Positive group | 7 | 6.38±1.26** | 71.54±6.40** |
| DT groups | 8 | 7.30±1.77* | 69.25±4.35* |
| ZG groups | 8 | 7.22±2.65* | 70.68±8.51* |
| ZV groups | 8 | 6.51±0.71** | 71.96±6.85** |
| DT+ZG groups（1） | 8 | 5.41±0.82*** | 74.27±8.28*** |
| DT+ZG groups（2） | 8 | 6.89±0.62** | 70.27±6.97** |
| DT+ZG groups（3） | 8 | 6.46±0.75** | 68.27±7.53** |
Note:Compared with normal group, #P< 0. 05;Compared with model group, * P<0.05.
As shown in Table 3, COPD rat models group is unbalance in the presence of one anti-oxidation stress of obvious oxidation, each medicinal portion of panax japonicus
It is unbalance that position can intervene adjustable body internal oxidition, mitigates oxidative damage.This is probably that each administration group improves rat model flow limitation
One of mechanism.
Table 4:TNF-α, IL-10 measurement results (x ± s)
| Group | Number of cases | TNF-α (OD values) | IL-10 (OD values) |
| Normal group | 8 | 0.35±0.21 | 0.28±0.04 |
| Model group | 8 | 0.97±0.20## | 0.19±0.04## |
| Positive group | 7 | 0.54±0.12** | 0.26±0.03** |
| DT groups | 8 | 0.69±0.22** | 0.27±0.04** |
| ZG groups | 8 | 0.57±0.14* | 0.26±0.03** |
| ZV groups | 8 | 0.60±0.12** | 0.27±0.04** |
| DT+ZG groups（1） | 8 | 0.44±0.13*** | 0.28±0.03** |
| DT+ZG groups（2） | 8 | 0.60±0.10** | 0.24±0.06** |
| DT+ZG groups（3） | 8 | 0.54±0.09** | 0.25±0.05** |
Note:Compared with normal group, #P< 0. 05;Compared with model group, * P<0.05.
As shown in Table 4, compared with normal group, model group rats serum TNF-cc level is significantly raised, IL-10 levels are obvious
Reduction, difference has conspicuousness (P<0.01)；Compared with model group, TNF-α content, liter are can obviously reduce after each administration group treatment
High IL-10 contents, difference has conspicuousness (P<0.01 or P<0.05), showing each administration group can reduce inflammation factor pair lung group
The damage knitted.
In summary, panax japonicus total polysaccharide, panax japonicus total saponins, panax japonicus saponin V and panax japonicus total polysaccharide and panax japonicus
The mixture of total saposins can effectively mitigate COPD flow limitation, uncomfortable in chest caused by preventing and treating COPD, the disease such as breathe heavily, have difficulty in breathing
Shape, vivo oxidation that its mechanism may can adjust COPD with panax japonicus polysaccharides and panax japonicus saponin is unbalance, nitric oxide production generation
And the damage for the factor pair lung tissue that reduces inflammation is relevant, and using the ratio of panax japonicus total polysaccharide and panax japonicus total saponins as 1:1
Mixture drug effect is optimal.
Embodiment described above is only the preferred embodiment to absolutely prove the present invention and being lifted, protection model of the invention
Enclose not limited to this.Equivalent substitute or conversion that those skilled in the art are made on the basis of the present invention, in the present invention
Protection domain within.Protection scope of the present invention is defined by claims.
Claims (4)
1. the composition of panax japonicus polysaccharides, panax japonicus total saponins or panax japonicus polysaccharides and panax japonicus total saponins is preparing prevention and controlled
Treat the application in the medicine of COPD.
2. application according to claim 1, it is characterised in that panax japonicus polysaccharides and panax japonicus total saponins in the composition
Mass ratio be 1:3~3:1.
3. application according to claim 2, it is characterised in that panax japonicus polysaccharides and panax japonicus total saponins in the composition
Mass ratio be 1:1.
4. applications of the panax japonicus saponin V in the medicine for preparing prevention and treatment COPD.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410721839.4A CN104490965B (en) | 2014-12-03 | 2014-12-03 | The application of panax japonicus polysaccharides, panax japonicus total saponins and panax japonicus saponin V |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410721839.4A CN104490965B (en) | 2014-12-03 | 2014-12-03 | The application of panax japonicus polysaccharides, panax japonicus total saponins and panax japonicus saponin V |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104490965A CN104490965A (en) | 2015-04-08 |
| CN104490965B true CN104490965B (en) | 2017-08-18 |
Family
ID=52932479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410721839.4A Active CN104490965B (en) | 2014-12-03 | 2014-12-03 | The application of panax japonicus polysaccharides, panax japonicus total saponins and panax japonicus saponin V |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104490965B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106880654B (en) * | 2017-04-11 | 2020-09-29 | 中南民族大学 | Application of panax japonicus extract in preparing medicine for treating rhinitis and composition |
| CN115611995B (en) * | 2022-12-05 | 2023-03-17 | 东北师范大学 | Panax japonicus polysaccharide and preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102247391A (en) * | 2010-05-19 | 2011-11-23 | 杨小林 | Application of panax japonicus saponin V to reduction of blood fat |
| CN102247417A (en) * | 2010-05-19 | 2011-11-23 | 杨小林 | Fat reduction effect of total saponins and polysaccharides of Panax japonicus |
| CN102247418A (en) * | 2010-05-19 | 2011-11-23 | 杨小林 | Liver protection effect of panax japonicus total saponin and panax japonicus polysaccharide |
-
2014
- 2014-12-03 CN CN201410721839.4A patent/CN104490965B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102247391A (en) * | 2010-05-19 | 2011-11-23 | 杨小林 | Application of panax japonicus saponin V to reduction of blood fat |
| CN102247417A (en) * | 2010-05-19 | 2011-11-23 | 杨小林 | Fat reduction effect of total saponins and polysaccharides of Panax japonicus |
| CN102247418A (en) * | 2010-05-19 | 2011-11-23 | 杨小林 | Liver protection effect of panax japonicus total saponin and panax japonicus polysaccharide |
Non-Patent Citations (4)
| Title |
|---|
| Protective Effect of Ginsenoside RO on Anoxic and Oxidative Damage In vitro;Zhou Jiang,et al.;《BIOMOLECULES&THERAPEUTICS》;20121231;第20卷(第6期);544-549 * |
| 慢性阻塞性肺病患者氧化与抗氧化失衡的研究;杨岚等;《陕西医学杂志》;19971031;第26卷(第10期);637-638 * |
| 竹节参多糖对小鼠血液SOD、CAT、MDA影响的研究;许彬等;《中国医院药学杂志》;20090531;第29卷(第9期);736-737 * |
| 竹节参皂苷药理作用研究进展;张小鸿等;《天然产物研究与开发》;20131231;第25卷;153-156、78 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104490965A (en) | 2015-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104013668B (en) | Licoflavone class extract is used to prepare to be applied in treatment ulcerative colitis medicine | |
| CN104490965B (en) | The application of panax japonicus polysaccharides, panax japonicus total saponins and panax japonicus saponin V | |
| CN103127273B (en) | Compound medicament for treating chronic liver disease and preparation method thereof | |
| CN107266599B (en) | Flammulina velutipes, extracting method and its application in terms of functional consitipation drug is treated in preparation | |
| CN106334171B (en) | A kind of Chinese medicine preparation and preparation method for being used to repair hepatic injury | |
| CN113694078B (en) | Application of vinegar-roasted schisandra polysaccharide extract in preparation of medicine for treating diabetes | |
| CN102824469B (en) | Detoxification traditional Chinese medicine and preparation method thereof | |
| CN101095700A (en) | Method for preparation of fermentation cordyceps active site and the application thereof in the aspect of respiratory disease | |
| CN104825750B (en) | The preparation of a kind of Flos Ginseng processed and preparation method | |
| CN104840737B (en) | Chinese medicine composition with qi invigorating and lung moistening effect and its preparation method and application | |
| CN104490904B (en) | It is a kind of to treat neurasthenic pharmaceutical composition and preparation method thereof | |
| CN104095912B (en) | Treat the preparation method of the Chinese patent drug of rheumatism bone disease | |
| CN103933386B (en) | Compound hemophiliac capsule used for treating hemophilia and preparation method thereof | |
| CN103768153B (en) | Traditional Chinese medicine composition for treating air sacculitis of poultry and preparation method thereof | |
| CN101721450B (en) | Application of oriental cocklebur root chloroform extract used for treating peritonitis | |
| CN105233252A (en) | Chinese and western medicine compound preparation for treating acute suppurative cholangitis | |
| CN105106634A (en) | Traditional Chinese medicine preparation for treating acute appendicitis and application thereof | |
| CN110025011A (en) | A kind of Radix Ophiopogonis ginseng lozenge of strengthen immunity | |
| CN115400171B (en) | Traditional Chinese medicine composition for treating wind-cold type common cold and preparation method thereof | |
| CN108324829A (en) | A kind of Hemorrhagic shock mixture and preparation method thereof containing ginseng | |
| CN113827636B (en) | Lung-clearing mixture containing Tibetan four ingredients and application thereof in preparation of medicines for treating respiratory system diseases | |
| CN108478701A (en) | A kind of lozenge of strengthen immunity | |
| CN115400161B (en) | Traditional Chinese medicine composition for treating summer-heat dampness cold and preparation method thereof | |
| CN103585302B (en) | The application of the extracts such as a kind of Song Sheng in preparation treatment diabetes medicament | |
| CN100522158C (en) | Application of Gulunbin, iso-gulunbin and fibleucin for preparing medicine for treating arthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |